✦ LIBER ✦

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

✍ Scribed by Robert J. Amato; Julie Ellerhorst; Cu Bui; Christopher J. Logothetis

Book ID: 116174092
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 621 KB
Volume: 1
Category: Article
ISSN: 1078-1439
DOI: 10.1016/1078-1439(95)00058-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Estramustine in combination with vinblas

Estramustine in combination with vinblastine and mitomycin-C for patients with progressive androgen independent adenocarcinoma of the prostate

✍ Amato, R J; Bui, C; Logothetis, C J 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 77 KB

The pattern of serum markers in patients

The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate

✍ Jeri Kim; J.Lynn Palmer; Laury Finn; Sherie Hodges; Victoria Bowes; Leonard Deft 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Absence of antitumor activity with predn

Absence of antitumor activity with prednisone in patients with progressive androgen-independent prostate carcinoma

✍ Robert J. Amato; Julie Ellerhorst; Laury Finn; Christopher J. Logothetis 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 458 KB

868 A tolerance and efficacy study of th

868 A tolerance and efficacy study of thalidomide, paclitaxel, estramustine combination for patients with chemotherapy refractory androgen independent prostate carcinoma

✍ D. Daliani; P. Dieringer; P. Matthew; L. Pagliaro; K. Davies; N. Tannir; I. Chen 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Multicenter Phase II study of estramusti

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma

✍ David J. Vaughn; Archie W. Brown Jr.; W. Graydon Harker; Sang Huh; Lance Miller; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Abstract ## BACKGROUND The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen‐independent prostate carcinoma (AIPC). ## METHODS Patients with progressive AIPC received 90 mg/m^2^ paclitaxel by 1‐ho

Intravenous vinorelbine (i.v.VRL) and es

Intravenous vinorelbine (i.v.VRL) and estramustine (EMP) in patients (pts) with androgen-independent prostate cancer (AIPC): final results

✍ J. Carles; R. Bastus; J. Martin-Broto; P. Maroto; M. Nogue; M. Domenech; A. Arcu 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 194 KB